Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gag-Protease Sequence Evolution Following Protease Inhibitor Monotherapy Treatment Failure in HIV-1 Viruses Circulating in East Africa.
Sutherland KA, Goodall RL, McCormick A, Kapaata A, Lyagoba F, Kaleebu P, Thiltgen G, Gilks CF, Spyer M, Kityo C, Pillay D, Dunn D, Gupta RK; DART Virology Group; DART Trial Team. Sutherland KA, et al. Among authors: kapaata a. AIDS Res Hum Retroviruses. 2015 Oct;31(10):1032-7. doi: 10.1089/aid.2015.0138. Epub 2015 Aug 10. AIDS Res Hum Retroviruses. 2015. PMID: 26258548 Free PMC article.
Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial.
Sutherland KA, Parry CM, McCormick A, Kapaata A, Lyagoba F, Kaleebu P, Gilks CF, Goodall R, Spyer M, Kityo C, Pillay D, Gupta RK; DART Virology Group. Sutherland KA, et al. Among authors: kapaata a. PLoS One. 2015 Sep 18;10(9):e0137834. doi: 10.1371/journal.pone.0137834. eCollection 2015. PLoS One. 2015. PMID: 26382239 Free PMC article. Clinical Trial.
From antiretroviral therapy access to provision of third line regimens: evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults.
Namakoola I, Kasamba I, Mayanja BN, Kazooba P, Lutaakome J, Lyagoba F, Kapaata AA, Kaleebu P, Munderi P; CoLTART study team. Namakoola I, et al. Among authors: kapaata aa. BMC Res Notes. 2016 Dec 23;9(1):515. doi: 10.1186/s13104-016-2309-7. BMC Res Notes. 2016. PMID: 28010730 Free PMC article.
Virological Response and Antiretroviral Drug Resistance Emerging during Antiretroviral Therapy at Three Treatment Centers in Uganda.
Kaleebu P, Kirungi W, Watera C, Asio J, Lyagoba F, Lutalo T, Kapaata AA, Nanyonga F, Parry CM, Magambo B, Nazziwa J, Nannyonjo M, Hughes P, Hladik W, Ruberantwari A, Namuwenge N, Musinguzi J, Downing R, Katongole-Mbidde E; HIV Drug Resistance Working group. Kaleebu P, et al. Among authors: kapaata aa. PLoS One. 2015 Dec 23;10(12):e0145536. doi: 10.1371/journal.pone.0145536. eCollection 2015. PLoS One. 2015. PMID: 26700639 Free PMC article.
Correction: Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial.
Sutherland KA, Parry CM, McCormick A, Kapaata A, Lyagoba F, Kaleebu P, Gilks CF, Goodall R, Spyer M, Kityo C, Pillay D, Gupta RK; DART Virology Group. Sutherland KA, et al. Among authors: kapaata a. PLoS One. 2016 Jun 2;11(6):e0157094. doi: 10.1371/journal.pone.0157094. eCollection 2016. PLoS One. 2016. PMID: 27254277 Free PMC article.
27 results